Pemoline (Cylert): market withdrawal.
Hogan
V
V
D016907:Adverse Drug Reaction Reporting Systems; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D002170:Canada; D000697:Central Nervous System Stimulants / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D004345:Drug Industry; D006801:Humans; D017093:Liver Failure / Q000139:chemically induced*; D008389:Marketing of Health Services; D010389:Pemoline / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment
D000697:Central Nervous System Stimulants; D010389:Pemoline